Stereoselective disposition of talinolol in man

Journal of Pharmaceutical Sciences

Volumn 91, Issue 2, 2002, Pages 303-311

  Zschiesche, Michael ^a   Lemma, Girum Lakew ^a   Klebingat, Klaus Jürgen ^a   Franke, Gerd ^a   Terhaag, Bernd ^a,b   Hoffmann, Anna ^a,b   Gramatté, Thomas ^a,c   Kroemer, Heyo K ^a   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Arzneimittelwerk Dresden GmbH   (Germany)

^c APOGEPHA Arzneimittel GmbH   (Germany)

Author keywords

Man; P glycoprotein; Racemate; Talinolol

Indexed keywords

KETOCONAZOLE; RIFAMPICIN; TALINOLOL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; LIVER MICROSOME; MALE; NORMAL HUMAN; PHENOTYPE; PROTEIN EXPRESSION; STEREOCHEMISTRY;

EID: 0036174253     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10054     Document Type: Article

References (39)

1. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
2. The mechnism of ATP-dependent multidrug transport by P-glycoprotein
3. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
4. The physiological function of drug-transporting P-glycoproteins
5. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein
6. The activity of verapamil as a resistance modifier in vitro in drug-resistant human tumour cell lines is not stereo-specific
7. The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil accross the rat jejunum
8. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats
9. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans
10. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites
11. Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans
12. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
13. 1-adrenoceptor antagonist talinolol in man
14. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
15. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
16. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration-and dose-dependent absorption in vitro and in vivo
17. Enantiomerentrennung durch HPLC an silicagel-gebundenen optisch aktiven Polyamiden
18. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
19. Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues
20. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
21. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
22. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein
23. Effect of quinidine on digoxin bioavailability
24. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)
25. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
26. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers
27. The interaction of digoxin and rifampin: Role of intestinal P-glycoprotein
28. Functional polymorphism of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
29. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma
30. Zur pharmakologie der optisch aktiven isomeren von talinolol (Cordanum®)
31. Dose-effect and kinetic-dynamic relationships of the β-adrenoceptor blocking properties of various doses of talinolol in healthy humans
32. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
33. Specificity of substrate and inhibitor probes for cytochrome p450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
34. Cytochrome P450 isoform inhibitors as tool for the investigation of metabolic reactions catalyzed by human liver microsomes
35. Effect of quinidine on the dextromethorphan O-demethylase activity of microsoma fraction from human liver
36. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
37. The nifedipine-rifampin interaction: Evidence for induction of gut wall metabolism
38. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
39. Modulators and substrates of p-glycoprotein and cytochromes P4503A coordinately up-regulate these proteins in human colon carcinoma cells